Abstract: For more than two decades, a powerful engine of discovery has been quietly advancing breast cancer research at the Rosalind & Morris Goodman Cancer Institute. The Breast Cancer Functional Genomics Group (BCFGG), led by Morag Park and managed by Hellen Kuasne, has built a remarkable research biobank containing over 2,400 patient samples linked with long-term clinical data, treatment responses, and patient outcomes. Unlike many collections that capture only a moment in time, this resource offers decades of follow-up data, allowing researchers to uncover patterns of disease progression, relapse, and survival. The biobank has also become a crucial resource in the fight against Triple Negative Breast Cancer, one of the most aggressive and difficult-to-treat breast cancer subtypes. With patient-derived xenografts, organoids, and advanced molecular profiling technologies such as spatial transcriptomics, researchers are mapping tumour behaviour and drug resistance with unprecedented detail. Supported by national collaborations including the Canadian Tissue Repository Network, this long-standing biobank is not just preserving samples, it is shaping the future of precision oncology and enabling discoveries that could transform how breast cancer is diagnosed and treated.
Get the full article here: https://www.goodmancancer.ca/en/news-details/gci-breast-cancer-biobank-tnbc-research-impact
